propafenone has been researched along with procainamide in 45 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (31.11) | 18.7374 |
| 1990's | 10 (22.22) | 18.2507 |
| 2000's | 15 (33.33) | 29.6817 |
| 2010's | 6 (13.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 2 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Alimuddin, M; Bulloch, D; Dahl, R; Grant, D; Lee, N; Peacock, M | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Boahene, KA; Fujimura, O; Klein, GJ; Sharma, AD; Yee, R | 1 |
| Brusca, A; Gaita, F; Giustetto, C; Mangiardi, L; Riccardi, R | 1 |
| Somberg, J | 1 |
| Roden, DM; Siddoway, LA; Woosley, RL | 1 |
| Huang, SK; Marcus, FI | 1 |
| Fenster, PE; Horwitz, L; Huang, SK; Kirsten, EB; Klein, RC; Marcus, FI; Rushforth, N | 1 |
| Ino, T; Karagueuzian, HS; Mandel, WJ; Meesmann, M; Ohta, M; Peter, T; Sugi, K | 1 |
| Condorelli, M; De Paola, M; Santinelli, V; Smimmo, D; Turco, P | 1 |
| Podrid, PJ | 1 |
| Atarashi, H; Hayakawa, H | 1 |
| Graboys, TB; Lampert, S; Lown, B; Podrid, PJ | 1 |
| Gang, ES; Hamer, A; Mandel, WJ; Oseran, DS; Peter, T; Rosenthal, ME | 1 |
| Somberg, JC | 1 |
| Fischer, M | 1 |
| Grey, E; Silverman, DI | 1 |
| Franz, MR; Koller, B | 1 |
| Derakhchan, K; Kus, T; Lambert, C; Pagé, P | 1 |
| Bourne, GW; Nattel, S; Talajic, M; Villemaire, C; Wang, J; Wang, Z | 1 |
| Chang, MS; Chen, SA; Chiang, CE; Ding, YA; Hsieh, MH; Tai, CT; Wen, ZC | 1 |
| Chang, MS; Chen, SA; Ding, YA; Feng, AN; Kuo, BI; Lee, SH; Tai, CT; Yu, WC | 1 |
| Fabritz, CL; Franz, MR; Kirchhof, PF | 1 |
| Lucchi, GR; Mattioli, AV; Mattioli, G; Vivoli, D | 1 |
| Geelen, P; O'Hara, GE; Plante, S; Roy, D; Roy, N; Talajic, M; Turgeon, J | 1 |
| Dell'Orfano, JT; Luck, JC; Naccarelli, GV; Patel, HM; Wolbrette, DL | 1 |
| Ishii, K; Kubota, Y; Moriuchi, H; Nakahara, T; Sakamato, K; Shigenobu, K; Tanaka, Y; Yunoki, M | 1 |
| Klein, GJ; Krahn, AD; Lee, JK; Simpson, C; Skanes, A; Spindler, B; Yee, R; Zarnke, K | 1 |
| Dorian, P; Pinter, A | 1 |
| Bonatti, S; Bonetti, L; Mattioli, AV; Mattioli, G | 1 |
| BORIS, A; MOE, RA; SCHALLEK, WE | 1 |
| Klein, GJ; Krahn, AD; Lee, JK; Simpson, C; Skanes, A; Yee, R; Zarnke, K | 1 |
| Chlouverakis, GI; Hamilos, ME; Igoumenidis, NE; Kochiadakis, GE; Marketou, ME; Vardas, PE | 1 |
| Calvelli, A; Chiatto, M; De Donato, V; De Rosa, F; Mancuso, P; Mazza, S; Spadafora, G | 1 |
| Faggioni, M; Hasdemir, C; Hwang, HS; Knollmann, BC; Laver, D; Mehra, D; Turhan, K; Yin, H | 1 |
| Birnie, D; Blecher, GE; Borgundvaag, B; Brison, RJ; Clement, CM; Lang, E; Langhan, T; Magee, K; Perry, JJ; Rowe, BH; Stenstrom, R; Stiell, IG; Wells, GA | 1 |
8 review(s) available for propafenone and procainamide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Antiarrhythmic drug therapy. Recent advances and current status.
Topics: Adrenergic beta-Antagonists; Ajmaline; Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Benzeneacetamides; Bepridil; Bethanidine; Bretylium Tosylate; Disopyramide; Drug Administration Schedule; Encainide; Flecainide; Heart Conduction System; Humans; Imidazoles; Lidocaine; Mexiletine; Moricizine; Myocardial Contraction; Phenothiazines; Phenytoin; Piperidines; Procainamide; Propafenone; Propiophenones; Pyrrolidines; Quinidine; Tocainide; Verapamil | 1985 |
Clinical pharmacology of old and new antiarrhythmic drugs.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anilides; Anti-Arrhythmia Agents; Benzeneacetamides; Biological Availability; Bretylium Compounds; Disopyramide; Encainide; Flecainide; Humans; Imipramine; Lidocaine; Mexiletine; Moricizine; Phenothiazines; Phenytoin; Piperidines; Procainamide; Propafenone; Propiophenones; Quinidine; Tocainide | 1985 |
Antiarrhythmic drug therapy of ventricular arrhythmias.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bretylium Tosylate; Disopyramide; Flecainide; Heart Ventricles; Humans; Lidocaine; Mexiletine; Moricizine; Phenothiazines; Phenytoin; Piperidines; Procainamide; Propafenone; Propiophenones; Quinidine; Sotalol; Tocainide; Verapamil | 1986 |
[Propafenone--a new generation anti-arrhythmia agent].
Topics: Administration, Oral; Anti-Arrhythmia Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Injections, Intravenous; Procainamide; Propafenone; Propiophenones | 1980 |
Cost-effective management of acute atrial fibrillation: role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy.
Topics: Algorithms; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cost-Benefit Analysis; Echocardiography, Transesophageal; Electric Countershock; Flecainide; Humans; Procainamide; Propafenone; Quinidine; Sotalol; Verapamil | 2000 |
Intravenous antiarrhythmic agents.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Infusions, Intravenous; Procainamide; Propafenone; Tachycardia, Ventricular | 2001 |
[Ventricular preexcitation: is risk stratification feasible?].
Topics: Adolescent; Adult; Age Distribution; Ajmaline; Atrioventricular Node; Catheter Ablation; Child; Child, Preschool; Clinical Trials as Topic; Death, Sudden, Cardiac; Electrocardiography; Exercise Test; Feasibility Studies; Female; Heart Function Tests; Humans; Male; Middle Aged; Procainamide; Prognosis; Propafenone; Risk Assessment; Sex Distribution; Wolff-Parkinson-White Syndrome; Young Adult | 2010 |
10 trial(s) available for propafenone and procainamide
| Article | Year |
|---|---|
Termination of acute atrial fibrillation in the Wolff-Parkinson-White syndrome by procainamide and propafenone: importance of atrial fibrillatory cycle length.
Topics: Adolescent; Adult; Aged; Atrial Fibrillation; Echocardiography; Female; Humans; Male; Middle Aged; Procainamide; Propafenone; Wolff-Parkinson-White Syndrome | 1990 |
[Propafenone--a new generation anti-arrhythmia agent].
Topics: Administration, Oral; Anti-Arrhythmia Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Injections, Intravenous; Procainamide; Propafenone; Propiophenones | 1980 |
Effects of antiarrhythmic drugs on variability of ventricular rate and exercise performance in chronic atrial fibrillation complicated with ventricular arrhythmias.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Blood Pressure; Chi-Square Distribution; Chronic Disease; Electrocardiography, Ambulatory; Exercise Tolerance; Female; Heart Rate; Humans; Male; Middle Aged; Procainamide; Propafenone; Sotalol; Tilt-Table Test; Treatment Outcome; Ventricular Dysfunction, Left | 1998 |
Tachycardia-induced change of atrial refractory period in humans: rate dependency and effects of antiarrhythmic drugs.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Electrophysiology; Female; Humans; Male; Middle Aged; Pacemaker, Artificial; Procainamide; Propafenone; Propranolol; Sotalol; Tachycardia, Supraventricular; Verapamil | 1998 |
Propafenone versus procainamide for conversion of atrial fibrillation to sinus rhythm.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Tolerance; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Procainamide; Propafenone; Time Factors | 1998 |
Comparison of propafenone versus procainamide for the acute treatment of atrial fibrillation after cardiac surgery.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Coronary Artery Bypass; Double-Blind Method; Drug Administration Schedule; Electrocardiography, Ambulatory; Female; Heart Rate; Heart Valves; Humans; Hypotension; Infusions, Intravenous; Male; Middle Aged; Procainamide; Propafenone; Treatment Outcome | 1999 |
Rate-control versus conversion strategy in postoperative atrial fibrillation: a prospective, randomized pilot study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Digoxin; Drug Administration Routes; Electric Countershock; Electrocardiography; Female; Heart Rate; Humans; Length of Stay; Male; Pilot Projects; Procainamide; Prognosis; Propafenone; Prospective Studies; Recurrence; Sotalol | 2000 |
Left atrial size after cardioversion for atrial fibrillation: effect of external direct current shock.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function, Left; Blood Flow Velocity; Echocardiography; Electric Countershock; Female; Heart Atria; Humans; Male; Middle Aged; Procainamide; Propafenone; Recurrence; Statistics as Topic; Stroke Volume; Treatment Outcome | 2003 |
Rate-control versus conversion strategy in postoperative atrial fibrillation: trial design and pilot study results.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmia, Sinus; Atrial Fibrillation; Atrioventricular Node; Calcium Channel Blockers; Cardiac Surgical Procedures; Electric Countershock; Female; Heart Rate; Heart Ventricles; Humans; Length of Stay; London; Male; Middle Aged; Pilot Projects; Postoperative Complications; Procainamide; Propafenone; Prospective Studies; Recurrence; Sotalol; Survival Analysis; Treatment Outcome | 2003 |
A comparative study of the efficacy and safety of procainamide versus propafenone versus amiodarone for the conversion of recent-onset atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Injections, Intravenous; Male; Middle Aged; Procainamide; Propafenone; Prospective Studies; Single-Blind Method | 2007 |
28 other study(ies) available for propafenone and procainamide
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding | 2002 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Determination of log D via automated microfluidic liquid-liquid extraction.
Topics: Automation; Biopharmaceutics; Microfluidic Analytical Techniques; Pharmacokinetics | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Stress and pharmacologic tests as methods to identify patients with Wolff-Parkinson-White syndrome at risk of sudden death.
Topics: Adolescent; Adult; Child; Death, Sudden; Exercise Test; Female; Humans; Male; Middle Aged; Procainamide; Propafenone; Risk Factors; Wolff-Parkinson-White Syndrome | 1989 |
Enhanced antiarrhythmic efficacy of propafenone when used in combination with procainamide or quinidine.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Drug Synergism; Drug Therapy, Combination; Electrocardiography; Female; Humans; Male; Middle Aged; Procainamide; Propafenone; Quinidine; Stroke Volume | 1987 |
The efficacy of cibenzoline and propafenone against inducible sustained and nonsustained ventricular tachycardias in conscious dogs with isolated chronic right ventricular infarction: a comparative study with procainamide.
Topics: Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Disease Models, Animal; Dogs; Drug Evaluation, Preclinical; Electrocardiography; Female; Heart Ventricles; Imidazoles; Male; Myocardial Infarction; Procainamide; Propafenone; Tachycardia | 1986 |
Ventricular parasystole and ventricular couplets: a re-entry within the parasystolic focus?
Topics: Arrhythmias, Cardiac; Electrocardiography; Humans; Male; Middle Aged; Myocardial Contraction; Procainamide; Propafenone; Systole; Verapamil | 1987 |
Aggravation of ventricular arrhythmia. A drug-induced complication.
Topics: Anilides; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Disopyramide; Drug Evaluation; Electrocardiography; Encainide; Flecainide; Humans; Mexiletine; Piperidines; Procainamide; Propafenone; Propiophenones; Quinidine | 1985 |
[Anti-arrhythmia agents (I): Quinidine, procainamide, disopyramide, encainide, propafenone and flecainide].
Topics: Anilides; Anti-Arrhythmia Agents; Disopyramide; Encainide; Flecainide; Humans; Piperidines; Procainamide; Propafenone; Propiophenones; Quinidine | 1985 |
Use of short-term drug testing as part of a systematic approach for evaluation of antiarrhythmic drugs.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Evaluation; Electric Stimulation; Humans; Monitoring, Physiologic; Procainamide; Prognosis; Propafenone; Propiophenones; Quinidine; Time Factors | 1986 |
The yield of programmed ventricular stimulation in mitral valve prolapse patients with ventricular arrhythmias.
Topics: Adult; Amiodarone; Arrhythmias, Cardiac; Electrocardiography; Electrophysiology; Female; Heart Arrest; Heart Ventricles; Humans; Male; Mexiletine; Middle Aged; Mitral Valve Prolapse; Procainamide; Propafenone; Propiophenones; Propranolol; Risk | 1985 |
New directions in antiarrhythmic drug therapy.
Topics: Adrenergic beta-Antagonists; Ajmaline; Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Benzeneacetamides; Bepridil; Bethanidine; Bretylium Tosylate; Death, Sudden; Disopyramide; Encainide; Flecainide; Humans; Lidocaine; Mexiletine; Moricizine; Phenothiazines; Piperidines; Procainamide; Propafenone; Propiophenones; Pyrrolidines; Quinidine; Tachycardia; Tocainide; Verapamil | 1984 |
Efficacy of type 1C antiarrhythmic agents for treatment of resistant atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Disopyramide; Encainide; Female; Flecainide; Heart Rate; Humans; Male; Middle Aged; Procainamide; Propafenone; Quinidine; Recurrence; Retrospective Studies | 1993 |
New classification of moricizine and propafenone based on electrophysiologic and electrocardiographic data from isolated rabbit heart.
Topics: Action Potentials; Analysis of Variance; Animals; Electrocardiography; Electrophysiology; Female; Heart; In Vitro Techniques; Kinetics; Male; Moricizine; Procainamide; Propafenone; Rabbits; Sodium Channel Blockers | 1994 |
Effects of procainamide and propafenone on the composition of the excitable gap in canine atrial reentry tachycardia.
Topics: Action Potentials; Anesthesia; Animals; Atrial Flutter; Atrial Function; Chloralose; Diastole; Disease Models, Animal; Dogs; Female; Gap Junctions; Heart Atria; Heart Conduction System; Male; Procainamide; Propafenone; Refractory Period, Electrophysiological; Tachycardia; Tricuspid Valve | 1994 |
Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation. Importance of use-dependent effects on refractoriness.
Topics: Animals; Atrial Fibrillation; Atrial Function; Cardiac Pacing, Artificial; Dogs; Electric Stimulation; Female; Heart Conduction System; Male; Procainamide; Propafenone; Sotalol; Vagus Nerve | 1993 |
Postrepolarization refractoriness versus conduction slowing caused by class I antiarrhythmic drugs: antiarrhythmic and proarrhythmic effects.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Confounding Factors, Epidemiologic; Electrocardiography; Heart Conduction System; In Vitro Techniques; Myocardial Contraction; Procainamide; Propafenone; Rabbits | 1998 |
Involvement of K(+) channel in procainamide-induced relaxation of bovine tracheal smooth muscle.
Topics: Albuterol; Animals; Anti-Arrhythmia Agents; Bronchoconstrictor Agents; Bronchodilator Agents; Cattle; In Vitro Techniques; Methacholine Chloride; Mexiletine; Muscle Contraction; Muscle Relaxation; Muscle, Smooth; Potassium; Potassium Channels; Procainamide; Propafenone; Quinidine; Trachea | 2000 |
A comparison of some cardiac responses to Ro 2-5803 (Rythmol), quinidine and procaine amide in laboratory animals.
Topics: Animals; Animals, Laboratory; Anti-Arrhythmia Agents; Procainamide; Propafenone; Quinidine | 1961 |
Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
Topics: Analysis of Variance; Animals; Anti-Arrhythmia Agents; Calcium Channel Blockers; Calsequestrin; Defibrillators, Implantable; Disease Models, Animal; Dose-Response Relationship, Drug; Electric Countershock; Electrocardiography; Flecainide; Humans; Ion Channel Gating; Lidocaine; Male; Mice; Mice, Knockout; Mutation, Missense; Myocytes, Cardiac; Procainamide; Propafenone; Ryanodine Receptor Calcium Release Channel; Sodium Channel Blockers; Tachycardia, Ventricular; Time Factors; Young Adult | 2011 |
Use of rate control medication before cardioversion of recent-onset atrial fibrillation or flutter in the emergency department is associated with reduced success rates.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Canada; Electric Countershock; Female; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Premedication; Procainamide; Propafenone; Retrospective Studies; Treatment Outcome | 2012 |